Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 56Recruiting 30Unknown 22Terminated 19Active not recruiting 7Not yet recruiting 5Withdrawn 2Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 38Other hematologic neoplasm 28Plasma cell 20CNS 14Gynecologic 11Sarcoma 9Myeloid 9Gastrointestinal 8Genitourinary 6Dermatologic 5Breast 4Thoracic 3Other 2Head & Neck 2Classical hematology 1

Conditions

Head and Neck Neoplasms 100Squamous Cell Carcinoma of Head and Neck 76Oropharyngeal Neoplasms 19Carcinoma, Squamous Cell 16Thyroid Neoplasms 15Carcinoma, Non-Small-Cell Lung 12Breast Neoplasms 11Carcinoma 10Neoplasms 9Mouth Neoplasms 9Laryngeal Neoplasms 9Tongue Neoplasms 8Lung Neoplasms 8Stomach Neoplasms 7Salivary Gland Neoplasms 7Neoplasm Metastasis 7Prostatic Neoplasms 6Ovarian Neoplasms 6Nasopharyngeal Carcinoma 6Hypopharyngeal Neoplasms 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Melanoma 5Esophageal Neoplasms 5Pancreatic Neoplasms 4Mucositis 4Carcinoma, Renal Cell 4Xerostomia 3

Interventions

Cetuximab 2Trastuzumab 1Sugars 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × Head & Neck × Clear all
NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01427205 2013-04-05

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡